Description
The successful candidate will have a minimum of one year of clinical fellowship training in neuromuscular disorders, including electrophysiology. In addition, the candidate will demonstrate outstanding interpersonal skills, collegiality, and personal effectiveness. The Neuromuscular Program has a robust clinical trials program and leads a national registry for rare neuromuscular disorders.
There will be opportunity to participate in the ALS multidisciplinary clinic, conduct electrophysiology studies, and deliver care in the Neuromuscular Clinic. There is the opportunity to do inpatient general neurology service at one of our Calgary hospitals, however this is negotiable. Within all clinical activity, it is anticipated that the successful candidate will contribute to education through clinical teaching of medical students, residents, and neuromuscular fellows including bedside teaching.
- The candidate must be eligible for Licensure with the College of Physicians and Surgeons of Alberta.
- Fellow of the RCPSC
- Successfully completed CSCN Exams for electromyography and nerve conduction studies
- Minimum 1 year of neuromuscular fellowship training at a recognized academic institution
- Must read, write, and speak English
All qualified candidates are encouraged to apply; however, Canadians and Permanent Residents will be given priority.
Contact Dr. Lara Cooke, Division Head (lcooke@ucalgary.ca) with any inquiries regarding the position.
Interested parties are to email PDF versions of their CV and 3 references to Trena Guest via trena.guest@ahs.ca
Additional Information
- Position Classification: Short-term Locum
- FTE: 0.5
- Unit and Program: Clinical Neurosciences
- Specialty: Neurology
- Secondary Specialty: Neuromuscular Disorders
- Recruiting Organization: Alberta Health Services
- Sponsorship Eligible: No
- Compensation: Fee-For-Service
- The Practitioner is responsible for purchasing health and insurance benefits.
- Posting Date: Feb 16, 2024
- Posting Status: Open until a suitable candidate is found
- Target Start Date: May 1, 2024